San Diego’s Ambit Biosciences, which is developing anti-cancer compounds that block the activity of certain protein kinases, withdrew its IPO registration, according to a regulatory filing yesterday. The biotech filed to go public on Nov. 5, and had planned to raise more than $86 million. In a letter signed by CFO Alan Fuhrman, Ambit says the initial public offering would have been a discretionary financing, and currently available terms “are not sufficiently attractive” to continue with its IPO.
